

FUTURE PLANS AND USE OF [REDACTED]

FUTURE PLANS

See “Business — Strategies” for a detailed description of our future business plans and strategies.

USE OF [REDACTED]

We estimate that the aggregate net [REDACTED] to our Company from the [REDACTED] will be approximately HK\$[REDACTED] million, after deducting [REDACTED], fees and other estimated expenses in connection with the [REDACTED] paid and payable by us taking into account any additional [REDACTED] fee and assuming that the [REDACTED] is not exercised and an [REDACTED] of HK\$[REDACTED] per Share, being the mid-point of the indicative [REDACTED] range of HK\$[REDACTED] to HK\$[REDACTED] per Share.

We intend to apply such net [REDACTED] from the [REDACTED] for the following purposes:

- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for further development, commercialization and manufacturing of AxiLona EL-100, our Core Product, of which:
 - (i) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for continued development, planned clinical trials and regulatory registrations of AxiLona EL-100, of which
 - approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to fund our R&D activities, covering process validation materials, prototype development, and performance testing essential to expand the clinical applications of the AxiLona EL-100 to include protein detection functionality. We intend to upgrade the existing device by further developing surface modification and different capture probes, thereby delivering rapid, high-sensitivity protein detection with minimal user input. This feature will be applicable in various clinical fields, including the detection of specific protein biomarkers related to Alzheimer’s disease, aiding in its diagnosis. We completed the design for this functionality in March 2026, and plan to initiate the design verification and other preclinical studies.
 - approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the registrational clinical trial in China for the protein detection functionality of AxiLona EL-100 and for preparing registrational filings for this functionality in China. We plan to initiate a clinical trial in China to evaluate the clinical safety and efficacy of the upgraded version of AxiLona EL-100 integrating both nucleic acid detection and protein detection functionalities. The related costs are expected to include trial implementation fees, clinical consulting fees, medical statistical analysis, preclinical research expenses, ethics committee review fees, costs for material and consumables, and labor costs of the R&D and regulatory teams. We plan to initiate this trial in the fourth quarter of 2026.
 - approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the registrational clinical trial in the U.S. for the nucleic acid detection functionality of AxiLona EL-100 and for preparing registrational filings for AxiLona EL-100 in the U.S. We completed pre-clinical type testing in the U.S. for AxiLona EL-100’s nucleic acid detection functionality in March 2026, and plan to initiate a clinical trial in the U.S. in the third quarter of 2026 to evaluate the safety and efficacy of AxiLona EL-100 for its nucleic acid detection functionality.
 - (ii) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the commercialization of AxiLona EL-100, including expanding our

FUTURE PLANS AND USE OF [REDACTED]

in-house sales and marketing team and conducting academic promotion to expand our market presence. We plan to allocate (a) approximately [REDACTED]%, or HK\$[REDACTED] million, to build a dedicated in-house salesforce with extensive industry background and proven sales records across both China and the U.S., to facilitate rapid market entry and drive market penetration; and (b) approximately [REDACTED]%, or HK\$[REDACTED] million, to support academic marketing initiatives with KOLs, physicians and researchers, provide market education to potential customers, as well as participate in various academic conferences and seminars, aimed at raising our brand awareness and publicizing our products.

- (iii) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for upgrading the existing production line for AxiLona EL-100, primarily through the following ways: (i) insourcing previously outsourced processes to in-house manufacturing, thereby boosting gross margins and enhancing supply chain control; (ii) implementing automation in critical production steps to improve efficiency, scalability, and product-quality consistency ahead of broader commercial launch; and (iii) procuring additional equipment to lower unit production costs and expand capacity to meet anticipated market growth.
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for further development, commercialization and manufacturing of AxiLona AXP-100, of which:
 - (i) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for continued development, planned clinical trials and regulatory registrations of AxiLona AXP-100, of which
 - approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the continued upgrade and iteration of AxiLona AXP-100. Specifically, we plan to continuously optimize biochemical performance, enhance sequencing accuracy, establish multi-chip parallel processing capabilities, improve throughput, shorten detection process time, and reduce device size of AxiLona AXP-100. We completed the type testing for AxiLona AXP-100 in China in December 2025, and are currently working with clinical trial institution to develop and prepare the clinical trial protocol.
 - approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the registrational clinical trials in China and the U.S. for AxiLona AXP-100. We plan to launch clinical trials to assess its clinical safety and efficacy in both China and the U.S. by the third quarter of 2026 and the fourth quarter of 2026, respectively.
 - (ii) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the commercialization of AxiLona AXP-100, including expanding our in-house sales and marketing team and conducting academic promotion to expand our market presence. We plan to allocate (a) approximately [REDACTED]%, or HK\$[REDACTED] million, to build a dedicated in-house salesforce with extensive industry background and proven sales records across both China and the U.S.; and (b) approximately [REDACTED]%, or HK\$[REDACTED] million, to support continued academic marketing initiatives with KOLs, physicians and researchers, provide market education to potential customers, as well as participate in various academic conferences and seminars.
 - (iii) approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the construction of production line for AxiLona AXP-100, and purchasing production equipment to build up our manufacturing capacity for AxiLona AXP-100. We plan to build a new production line for AxiLona AXP-100, which is expected to boost the annual production capacity by 1,000 units of instruments and 100 thousand sets of compatible test kits.
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for the development of AxiLona AXP-1000 and our other pipeline products. We plan

FUTURE PLANS AND USE OF [REDACTED]

to complete the design of AxiLona AXP-1000 in the third quarter of 2026, featuring a higher throughput sequencing chip with ten million nanopore channels, offering nearly ten times the throughput of the AxiLona AXP-100.

- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used to expand and strengthen our core technology platform to further solidify our unique integration of integrated circuits (IC), biotechnology (BT), and artificial intelligence (AI). Specifically, we plan to (i) build a dedicated bio-chip packaging and integration line that completes semiconductor bio-chip encapsulation and microfluidic-cartridge assembly in-house by 2026. This technical upgrade is anticipated to enhance the production efficiency of test kits compatible with AxiLona EL-100; (ii) launch an AI-powered enzyme-engineering service by creating a proprietary database of protein data (including sequence, structure, function, and expression) to develop predictive models for specific applications, such as enzymes for isothermal multiplex PCR or those with high-salt tolerance and high fidelity. This service will establish a fully automated, closed-loop “design-build-test-learn” cycle, where the AI automatically generates new designs based on screening results to greatly accelerate enzyme evolution. We expect to begin delivering this service by 2027. The enzymes and proteins produced from this platform can also be incorporated into the test kits compatible for our AxiLona EL-100 and AxiLona AXP-100; and (iii) purchase additional computing servers to increase data processing speed and bioinformatics analysis capabilities by 2027, such as to train our deep learning-based algorithms for base recognition.
- approximately [REDACTED]%, or HK\$[REDACTED] million, will be used for working capital and general corporate purposes.

If the net [REDACTED] from the [REDACTED] exceed the above funding requirements and, to the extent permitted by applicable laws and regulations, we will use the surplus funds for working capital. If we urgently need the funds for the above purposes but cannot immediately obtain the net [REDACTED] from the [REDACTED], we will use self-raised funds to meet the relevant funding requirements and replace these self-raised funds with the net [REDACTED] from the [REDACTED] when the [REDACTED] become available to us. If the net [REDACTED] of the [REDACTED] are not immediately applied to the above purposes, we will only deposit those net [REDACTED] into short term interest-bearing accounts at licensed commercial banks and/or other authorized financial institutions in Hong Kong and the PRC (as defined under the SFO and the applicable laws and regulations in the PRC).

If the [REDACTED] is set at HK\$[REDACTED] per Share, being the high end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will increase to approximately HK\$[REDACTED] million. If the [REDACTED] is set at HK\$[REDACTED] per Share, being the low end of the indicative [REDACTED] range, the net [REDACTED] from the [REDACTED] will decrease to approximately HK\$[REDACTED] million. The above allocation of the net [REDACTED] from the [REDACTED] will be adjusted on a pro rata basis in the event that the [REDACTED] is fixed at a higher or lower level compared to the mid-point of the indicative [REDACTED] range stated in this document.

If the [REDACTED] is exercised in full, the net [REDACTED] that we will receive will be approximately HK\$[REDACTED] million, assuming an [REDACTED] of HK\$[REDACTED] per Share (being the mid-point of the indicative [REDACTED] range). In the event that the [REDACTED] is exercised, we intend to apply the additional net [REDACTED] to the above purposes in the proportions stated above.

If any part of our plan does not proceed as planned for reasons such as changes in government policies that would render any of our plans not viable, or the occurrence of force majeure events, our Directors will carefully evaluate the situation and may reallocate the net [REDACTED] from the [REDACTED].

We will issue an appropriate announcement if there is any material change to the above proposed use of [REDACTED].